



Brochure

Healthtech Innovation Days - 6th edition

A throwback on all conferences and HTID#6 key takeaways from each round tables. HealthTech Innovation Days is an event organized by HealthTech For Care.



organized by



ABOUT HEALTHTECH INNOVATION DAYS

Every year, HealthTech For Care, a non-profit organization, organizes the HealthTech Innovation Days (HTID).

HTID is a unique, non-profit European event that brings together key players in the health ecosystem: researchers, industry leaders, investors, regulators, patients & patient associations, as well as European and national institutions. Its goal is to put innovation at the service of patients by facilitating their access to the best therapies, without barriers, and to promote the development and access to breakthrough innovations for all European patients, with the support of public entities, to generate a global impact.

The event fosters dynamic interactions through 1to1 meetings among European companies, global investors, industrial and pharmaceutical groups, as well as patients and patient associations. Moreover, HTID includes conferences addressing crucial topics of general interest, guided by international experts, European Institutions and key opinion leaders (KOLs). Pitch sessions are also organized. Access to these sessions is available to everyone on the HealthTech For Care endowment fund website in replay.

We celebrated the 2024 6th edition on September 17th & 18th, in Paris.




ABOUT HEALTHTECH INNOVATION DAYS

The event is designed for:

- European healthtech companies (biotech, medtech, diagnostics, innovative services, and digital health), from Serie A to dual-listed companies,
- Investors,
- Pharmaceutical firms,
- Patients and patient associations,
- and Healthcare professionals such as lawyers, CROs, auditors, consulting firms...

HTFC Companies participation details for HTID





HEALTHTECH INNOVATION DAYS 6TH EDITION IN NUMBERS

23
sponsors

400+
attendees

55
Pharmaceutical
and other
companies

110
International
HealthTech
Companies

15
Countries
represented

25
Patients and
patient associations

80
Speakers

70
International
investors

290
1x1
Meetings

17
Sessions over
2 days



A quarter of the way into the XXIst Century: What progress, what lessons, and what future for Health Care?



Replay

Key takeaways:

- ➔ **Healthcare Advances:** Significant progress in medical treatments and technology, though healthcare has shifted from patient-centered care to a more commodified service. Healthcare breakthroughs since 2000 have increased global life expectancy by 10%
- ➔ **AI's Impact on Healthcare:** AI accelerates medical research but lacks the creativity needed for truly innovative questions, limiting its role to enhancing, not transforming, healthcare.
- ➔ **Investment Disparity:** The U.S. biotech sector leads globally, while Europe lags due to fragmented markets and limited venture capital, despite strong research output.
- ➔ **Future M&A Trends:** Biopharma M&A is currently slow but expected to pick up post-2024, driven by patent expiries and the need for consolidation to sustain growth.

With the participation of :



Francois Maisonrouge
Senior Managing Director
Evercore Partners





Macro-Economic Environment and Financial Issues



Replay

Key takeaways:

- ➔ Investment is key, with public support for companies from the government.
- ➔ A recession in the US or Europe is unlikely. Central banks are expected to cut rates, stimulating the economy, easing financing, and boosting business activity as demand rises with inflation.
- ➔ Nations that embrace AI and digital advancements will thrive, while others risk falling behind. Governments should invest in startups to drive innovation and economic growth.
- ➔ Europe's healthtech sector is growing but lags behind the US in scale and ambition. While attracting global investors, Europe needs larger, riskier projects to match US innovation. The focus is shifting from funding many startups to fewer, better-funded ventures for stronger growth.

With the participation of :



Christian Pierret
Moderator



Amiram Appelbaum
Chairman
Israel Innovation
Authority



William De Vijlder
Group Chief
Economist
Bnp Paribas



Guillaume Morelli
Head of Listing
France & Iberia
Euronext





Entrepreneur testimony: Navigating Financial and Development Challenges



Replay 

Key takeaways:

- The importance of product differentiation,
- The necessity of having expert investors, a board of directors with diverse skills and profiles,
- Surrounding oneself with an experienced management team to address the complexity of clinical development.

With the participation of :



Marc de Garidel
CEO of Abivax and Chairman of
the Board at Ipsen





Therapeutic Adherence: Enhancing Doctor-Patient Relationships through Artificial Intelligence



Replay

Key takeaways:

- ➔ Lack of adherence is a major health issue, with 50% of cardiovascular disease patients not following their treatment, leading to over 200,000 preventable deaths annually in Europe.
- ➔ Collaboration among all stakeholders is crucial: Addressing this challenge requires working together, not assigning blame, and designing solutions that are intuitive and comfortable for patients.
- ➔ Digital health and AI can drive behavior change, playing a key role in improving treatment adherence by creating user-friendly solutions designed around specific patient needs.
- ➔ A comprehensive approach is needed, combining education, awareness, simplified treatments, and systematic evaluation of digital tools to build trust between patients and physicians.

With the participation of :



Tamara Krcmar
Transversal Medical
Communication Director
Servier



Elie Lobel
CEO
RDS Diag





Life Sciences Transaction Trends



[Replay](#)

Key takeaways:

- ➔ Transactions, whether business development or financing, are still a challenge in 2024, in particular in Europe vs. US.
- ➔ At the same time, some companies can experience rapid successes and deals: the market is more polarized, between high quality assets that get deals and financing, and the rest who are facing difficult times.
- ➔ The market seems to be picking up and 2025 is expected to mark a real rebound - stay tuned!

With the participation of :



Elsy Boglioli Hofman
Moderator



Emmanuelle Porte
Co-Managing Partner
Bird & Bird



Alain Decombe
Partner
Dechert LLP



Antoine Khallouf
Director
Rothschild & Co



Philippe Lopes Fernandes
CBO & VPE
Ipsen





Advancement in Obesity Management



[Replay](#)

Key takeaways:

- ➔ Obesity is not just a weight issue; it is a complex disease associated with major cardiovascular problems and inflammation. It can be sporadic or hereditary. While lifestyle changes (such as diet and exercise) are necessary, highly effective medications are now available to aid in weight loss.
- ➔ Effective Medications: GLP-1 and GIP treatments from Novo Nordisk and Eli Lilly offer significant weight loss and diabetes management, though tolerance can be an issue.
- ➔ Brain-Targeting Therapies: MC4 agonists are revolutionizing obesity treatment by altering brain signals, addressing hunger and rare genetic causes of the disease.
- ➔ Innovative Solutions: Startups like CaleeTech are developing products that reduce fat and sugar absorption, allowing patients to enjoy food without weight gain.

With the participation of :



Anne Moore
Moderator



Isabelle Lonjon-Domanec
VP Clinical, Medical &
Regulatory Affairs France
Novo Nordisk



Igor Gindin
Founder, CEO and
Chairman of the
Board
CaleeTech



Réginald Allouche
Founder and CEO
PALTech



Maithé Tauber
Pediatric endocrinologist,
head of the children's
department
CHU de Toulouse



Orphan Diseases: Engaging Patients in Clinical Trials



[Replay](#)

Key takeaways:

- ➔ Rare diseases, often genetic and starting in childhood, require early engagement with patients and associations to understand their needs before designing clinical development plans and trials.
- ➔ Understanding the patient's perspective on how the disease impacts their daily life helps define endpoints that are meaningful not only for regulatory approval but also for payers.
- ➔ In pharma, it's crucial to involve researchers and clinical teams with patients early on to gain real insights, ensuring relevance throughout development—a key factor for attracting investors.
- ➔ Agility in clinical development is essential to adapt study designs, routes of administration, and other factors to patient needs, supported by regulators, HTA bodies, and payers.

With the participation of :



Marc Deschamps
Moderator



Karen Aiach Pignet
Founder
Blue Daisy



Andrea Ballerini
Associate
Panakes Partners



Nicolas Levy
Chief Scientist Rare
Diseases
Servier



Philippe Picaut
Chief Development
Officer
AlgoTherapeutix



François Rauch
General Manager
France Belux
ArgenX





Challenges and Rewards of Investing in Breakthrough Innovation



Replay 

Key takeaways:

- ➔ While digitalization has slowed healthcare delivery, advancements in AI are expected to enhance efficiency, moving us toward a more streamlined system soon.
- ➔ Digital therapeutics: Innovations like digital therapeutics can reduce care costs and improve patient access while integrating new technology.
- ➔ Bridging gaps: Educating academics about the drug discovery process is vital for effective collaboration with biotech and pharmaceutical groups, and training programs are essential.
- ➔ Cost-effective models: Transitioning healthcare delivery from one-to-one to one-to-many is essential to accommodate the growing biologic innovations.

With the participation of :



Gabriela Apiou
Moderator



Robert Tepper
Co-founder and Partner
Third Rock Ventures



Timothy Ferris
M.D., M.P.H.
Harvard University, MIT,
Brandeis University





Health & Space: Beyond Earth



[Replay](#)

Key takeaways:

- ➔ Health events like HTID are crucial platforms to engage health communities and introduce disruptive innovations derived from space research.
- ➔ Educating life science and health investors about the emerging 'health from space' markets is essential. A special MasterClass for investors will be held in December 2024 to address this.
- ➔ Success stories from space experiments over the past two decades on the International Space Station highlight the potential for new pharmaceutical and medical breakthroughs.
- ➔ Bottlenecks in developing space-based health solutions include a lack of physics and space education in the health community and insufficient investor funding, particularly in Europe compared to the U.S.

With the participation of :



Paul Kamoun
Moderator



Gianluigi Baldesi
Head of Ventures and
Financing Office
European Space
Agency



Azita Djilivand
Medical Director
Roche Diagnostics



Luc Berger
Partner, Chief
Explorer Healthcare
Alcimed



**Jean-Philippe
Annereau**
CEO
Medetia



Jean-Claude Vecchiato
Global Space and Satellite
Practice Director, Aerospace
and Defense Director for France
Bird & Bird



How are new FDA developments and shifting political environment impacting EU-based Life Sciences companies US entry strategy?



[Replay](#)

Key takeaways:

- ➔ Artificial intelligence technologies hold the promise of, and have already demonstrated, immense efficiencies and improvements in the clinical trial operations of life sciences companies, from drug discovery to approval.
- ➔ As FDA regulations evolve in response to the continued integration of artificial intelligence technologies into clinical trial operations by both life sciences companies and the FDA itself, it is vital that life sciences companies engage with the FDA to ensure stakeholder interests and concerns are adequately addressed.
- ➔ Additionally, as shifting political landscapes in the United States—both in the past year and due to the upcoming election—may materially affect the FDA’s regulatory position and authority, life sciences companies looking to enter the U.S. market must remain vigilant about changes in the U.S. political and judicial environments.

With the participation of :



James Ravitz
Partner
McDermott Will & Emery





Emerging Countries' Access to Innovation: The Pricing Challenges



[Replay](#)

Key takeaways:

- ➔ **Global Scalability:** Life sciences products have global potential, highlighting the need for and the great opportunity to establish frameworks that facilitate innovation transfer and co-developments with emerging markets.
- ➔ **Investment Necessity:** Significant investments are essential to support innovation and ensure that products are accessible to low- and middle-income countries (LMICs).
- ➔ **Dual Focus on Impact:** There are opportunities to align financial success with societal impact, creating business models that benefit both companies and communities in LMICs, while also further benefiting other countries.
- ➔ **Foundation for Access:** Building strategic partnerships and innovative pricing models can help capture the global potential of life sciences products while addressing the unique challenges faced by emerging markets.

With the participation of :



Anaïs Le Corvec
Moderator



Rebecca Grais
Executive Director
Pasteur Network



José Castillo
Co-Founder
Univercells



Nina Rawal
Partner and Co-Head
Trill Impact





How to successfully implement your subsidiary and team overseas



[Replay](#) 

Key takeaways:

- ➔ **Local Expertise is Key:** Ensure you have trusted local partners or employees in place to help navigate regulations, accounting, and payroll. Their guidance is crucial to a smooth transition.
- ➔ **Strengthen Your Governance:** Consider adding a local board member (e.g., US-based for a US expansion) to boost credibility and provide investor protection. This step can also help you adapt to local business practices.
- ➔ **Protect Your Intellectual Property:** Before expanding, ensure that patents and licenses are secure and fully protected in the target country to avoid legal risks.

With the participation of :



Stamatiki Kritas
Moderator



Anne Juliette Hermant
Chief Human Resources Officer
Nanobiotix



Ida Hatoum
Chief Human Resources Officer
Abivax



Vassily Zvonov
Partner
Mazars





Success & Frustration: Personalized Medicine, Cell, and Gene Therapy Trends



[Replay](#)

Key takeaways:

- ➔ The field of personalized medicine has never seen so many approvals - a new and very positive dynamic
- ➔ At the same time, financing is still difficult, and commercialization can be tough too, so new challenges arise.
- ➔ On the positive side, regulatory agencies are positioning themselves as enablers, adjusting their positions and learning from the leaders, which is rare and very valuable.
- ➔ Overall given the number of trials and the promises of curative approaches, this field remains very attractive, and we hope to see new breakthroughs in the coming years

With the participation of :



**Elsy Boglioli
Hofman**
Moderator



Anne Moore
Principal
Roland Berger



Miguel Forte
Chief Executive
Officer
Kiji Therapeutics



Frédéric Desdouts
CEO
TreeFrog
Therapeutics



David Venables
CEO
Laverock





Convergence of Breakthrough Science and Capital



[Replay](#)

Key takeaways:

- ➔ Innovation is flourishing in the EU.
- ➔ Go big or go home: Focus on building large, well-financed, and strong companies.
- ➔ Fundraising: The EU is lagging behind the USA in raising sufficient capital to finance the biotech sector.

With the participation of :



Nissim Darvish
Moderator



Christian Homsy
Founder Capstan



Sonia Benhamida
Director BlackRock



Philippe Monteyne
Partner Aliath
Bioventures



Frederic Scaerou
Head of Global
Business
Development
Servier





Mental Health: Inside the Brain



[Replay](#)

Key takeaways:

- ➔ **Crisis and Awareness:** The COVID-19 pandemic has heightened mental health issues, but increased awareness is helping reduce stigma and encourage treatment.
- ➔ **Investment:** Small healthtech companies are driving innovations in mental health; they require significant investment to scale their solutions effectively.
- ➔ **Collaboration in Research:** Promoting multicenter studies among researchers can enhance understanding and treatment of mental health issues through shared knowledge and resources.
- ➔ **Policy and AI Integration:** Engaging policymakers for better reimbursement and integrating AI solutions can significantly improve mental health care access and effectiveness.

With the participation of :



Anaïs Le Corvec
Moderator



Michel Berg
Co-founder,
President and CEO MATCH4Innovation
Axilum Robotics



Véronique Narboni
Medical Director



Zofia Smoleń
Founder
MindMatch



Maria Nassif
Patient Ambassador
FH Europe
Foundation and
ANHET.F



Prospective healthcare and medicine of tomorrow



Key takeaways:

[Replay](#)

- ➔ Cities for Better Health (Novo Nordisk) and integrative medicine (Institut Rafael) focus on addressing global health through prevention and multidisciplinary care, combining traditional and advanced therapies to improve patient outcomes.
- ➔ "Home as a determinant of health" strategy (LaPosteSanté & Autonomie) leverages local presence for health management, integrating digital and in-person care to strengthen healthcare pathways and demonstrate measurable health impacts.
- ➔ SilverEconomy and elderly care partnerships (SweetHome) are key to providing innovative support for senior populations, offering enhanced services for aging well.
- ➔ Chronic disease prevention (Novo Nordisk) is crucial, especially in urban areas where diabetes and obesity are prevalent, underscoring the need for proactive health management throughout all stages of life.

With the participation of :



Ivan Cohen-Tanugi
Moderator



Florence Dupré
Global Healthcare
Officer
La Poste



Alexandre Faure
CEO
Sweet Home



Etienne Tichit
Managing Director
Novo Nordisk



Alain Toledano
Chairman
French Society of
Integrative
Oncology



A LOOK BACK ON THE THIRD EDITION OF THE PITCH SESSIONS

(20 PITCHING COMPANIES FROM 7 COUNTRIES)



Rosetta Omics is a French healthcare deeptech startup based in Paris, specializing in enhancing the prediction of treatment responses. The company provides physicians with critical insights to prescribe the most effective therapies at the right time, saving both lives and costs.

"Winning first place at the HealthTech Innovation Days is not just an award; it's a testament to our commitment to enhancing patient care and driving innovation in the healthcare ecosystem," said **Wahid Awad**, CEO and Founder of Rosetta Omics. "The conference was exceptionally well-organized, bringing together the best European companies and key opinion leaders (KOLs). We can't wait to return next year and present Rosetta again."

MIRA vision microscopy GmbH revolutionizes medical diagnostics with cutting-edge AI technology, enabling ultra-fast, highly accurate analyses in pathology—at a fraction of traditional costs. By leveraging fully parametric, synthetic data with unprecedented diversity, MIRA vision ensures both efficiency and comprehensive diagnostic capabilities. Our scalable and privacy-focused solutions are set to expand beyond pathology to transform the entire field of medical imaging and diagnostics.

"A big thank you to Sophie Villedieu and the entire team behind HTID6 for organizing such an outstanding event! It was a fantastic opportunity to connect with a diverse and inspiring network, and we truly appreciated the platform provided for meaningful exchanges. We would be thrilled to be part of this great initiative again in the future!" said **Lukas Mürdter**, CEO of MIRA vision



Allegro is on a mission to liberate 650 million patients from osteoarthritis. They bring a category innovation with the first disease modifying therapeutic based on our nanotechnology platform. Excellent preclinical and first-in-human results lead the way to a bright future with blockbuster potential.

"You could hear the crowd cheer from excitement at Allegro's HTID pitch." said **Lucas Decuypere**, CEO of Allegro

Thank you to all the pitching companies who took the time to present at HTID#6. Your pitches were highly convincing, and the jury greatly appreciated your efforts and dedication.



EDITO



“ Pierre Courteille

Chairman of HealthTech For Care



It was a great honor to welcome all participants to the 6th edition of the HealthTech Innovation Days (HTID#6). First and foremost, I would like to express my deepest gratitude to our valued sponsors, whose unwavering support is the cornerstone of this event's success. Over the course of these two days, the sessions offered invaluable opportunities for participants to engage with the entire ecosystem—researchers, entrepreneurs, investors, patient associations, and industry leaders alike. I am confident that you left the conference empowered with practical, actionable insights to drive your organizations forward and accelerate the transformation of the European healthcare landscape, ultimately benefiting patients.

”

“ Sophie Villedieu

Managing Director of HealthTech For Care

I want to deeply thank our sponsors, as well as all the attendees, including entrepreneurs, investors, pharma representatives, patient associations, and institutional participants. This edition received a high level of satisfaction featuring high-value content, networking opportunities, and pitch sessions. HTID offers a unique opportunity to connect with key stakeholders driving innovation in drug development.



”



A WORD FROM OUR ATTENDEES



“The place to be to meet innovative health leaders.”

“An incredible opportunity to connect with key stakeholders driving innovation in drug development.”

“The event of innovative opportunities.”

“Great and useful event!”

“Well balanced event with high value contents, nice networking, good pitch sessions, and cultural animation !”

“HTID6 was a truly enriching experience!”

“An excellent opportunity to hear from thought leaders on the latest critical topics in HealthTech. The convergence of profiles from across the ecosystem (pharma, biotech, startup, investor, academia) was well appreciated.”

“For me this edition of HTID was the best one I attend since its inception, the place of the event, the round tables and the quality of the pitches were very good!”



WE EXTEND OUR DEEPEST GRATITUDE
TO OUR ESTEEMED SPONSORS



WE EXTEND OUR DEEPEST GRATITUDE TO OUR ESTEEMED PARTNERS





**SEE YOU NEXT YEAR
FOR HTID#7**

OCTOBER 7-8, 2025 IN PARIS

**HEALTHTECH
INNOVATION DAYS**

Annual European event



by **HealthTech**
FOR CARE